Who
Richard W. Dugan
Director
Company insider
Files Form 4 as: Director, Vanda Pharmaceuticals; Director, MiddleBrook Pharmaceuticals; Director, Critical Therapeutics.
In numbers
- Trades disclosed
- 52
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $557K
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 25 Apr 2006
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —41,600 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —41,600 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —59,225 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —37,578 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —20,529 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —33,960 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —17,307 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —24,707 at $0.00 | filing |
| 16 Jun 2022filed 21 Jun 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —12,006 at $0.00 | filing |
| 31 May 2022filed 2 Jun 2022 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 31 May 2022filed 2 Jun 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $62K15,000 at $4.15 | filing |
| 31 May 2022filed 2 Jun 2022 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $64K6,500 at $9.85 | filing |
| 10 Jun 2021filed 14 Jun 2021 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 10 Jun 2021filed 14 Jun 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 16 Feb 2021filed 18 Feb 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $107K15,000 at $7.11 | filing |
| 16 Feb 2021filed 18 Feb 2021 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $107K5,754 at $18.54 | filing |
| 16 Feb 2021filed 18 Feb 2021 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 11 Jun 2020filed 15 Jun 2020 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 Jun 2020filed 15 Jun 2020 | VNDA Vanda PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 28 May 2020filed 29 May 2020 | VNDA Vanda Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
News
Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramVNDA · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Richard W. Dugan; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.